Agarwal 2013 KEN.

Methods	Trial design: An open label RCT Follow‐up: Followed up for 42 days and asked to return on days 1, 2, 3, 7, 14, 21, 28, 35, and 42 after enrolment or at any day if ill. Clinical assessment and blood smear at each visit. Hb measured on days 0, 7, 14, 28, and 42. Adverse event monitoring: Not reported. "Adverse events investigated and addressed".
Participants	Number of participants: 274 Inclusion criteria: Children aged 6 to 59 months with axillary temperature ≥ 37.5 °C or history of fever in preceding 48 hrs, weight ≥ 5.0 kg, parasitaemia, residing within 10 km of Siaya District Hospital, written informed consent. Exclusion criteria: Lethargy, convulsions, persistent vomiting, inability to drink, signs of severe malaria, severe anaemia (Hb < 5 g/dL), known hypersensitivity to trial drugs, presence of chronic medical conditions, treatment with any anti‐malarial in preceding two weeks, previous enrolment in any malaria trial, severe malnutrition (weight‐for‐age ≤ 3 standard deviations below mean for gender according to WHO standards).
Interventions	1. DHA‐P, fixed dose combination, 20 mg/160 mg tablets (DuoCotexin: Beijing Holley‐Cotec) 5 to 6 kg: one half tablet daily 7 to 9 kg: one tablet daily 10 to 14 kg: two tablets on day 0 then one tablet on days 1 and 2 15 to 19 kg: two tablets daily 2. Artemether‐lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novartis) 5 to 14 kg 1 tablet twice daily for 3 days 15 to 24 kg 2 tablets twice daily for 3 days 25 to 34 kg 3 tablets twice daily for 3 days All doses, except AL evening doses, administered under direct supervision.
Outcomes	ACPR at days 28 and 42, PCR‐unadjusted and PCR‐adjusted Mean change in Hb from baseline to day 28 Adverse events Not included in this review: Fever clearance Parasite clearance
Notes	Country: Kenya Setting: district hospital in western Kenya Transmission: Holoendemic with high transmission and two seasonal peaks, April to July and November to December Resistance: Not reported Dates: Oct 2010 to Aug 2011 Funding: KEMRI/CDC Research and Public Health Collaboration, Beijing Holley‐Cotec provided DHA‐P free of charge.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"children were block randomized in fixed blocks of ten to treatment".
Allocation concealment (selection bias)	Unclear risk	None described.
Blinding for microscopy outcomes (performance bias and detection bias)	Low risk	"All microscopists were blinded to the treatment arm".
Blinding for adverse events (performance and detection bias)	Unclear risk	No other blinding reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	Percentage withdrawn from analysis high in both treatment groups (17.5% DHA‐P versus 18.2% AL).
Selective reporting (reporting bias)	Low risk	All WHO outcomes reported.
Other bias	Low risk	No other forms of bias identified.